With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

C urrently, Ozempic is only approved to treat type 2 diabetes. But in recent years, the semaglutide injection has become a ...

China represents an untapped market for GLP-1 class diabetes drugs, according to Novo Nordisk, which is predicting "good momentum" for its already-approved Victoza, and its successor semaglutide.

Both products combine a long acting insulin with a GLP-1 analogue – Xultopy brings together Tresiba and Victoza, while Soliqua (formerly known as LixiLan) combines Lantus with Adlyxin (Lxyumia ...

All the latest breaking news on United States. Browse ibtimes archives of photos, videos and articles on United States.

Stanford Medicine researchers have identified a promising, naturally occurring molecule that could help people lose ...

Adults who frequently drink white wine are 22% more likely to develop skin cancer compared to those who regularly consume red wine, a new study has shown. Scientists from the Brown University School ...

Kidney transplant recipients with type 2 diabetes treated with a new class of anti-obesity drugs were less likely to ...

For people living with diabetes, these changes raise crucial questions about how care will be delivered, how decisions will be made and whether patient outcomes will improve as a result. Starmer has ...

New Tech for Managing Type 1 Diabetes Is Effective for Older Adults Mar. 11, 2025 — New research suggests that automated insulin delivery (AID) systems are safe and effective for use by older ...

G lucagon-like peptide-1 receptor agonists, aka GLP-1 agonists, such as semaglutide -- better known as Ozempic -- have ...

Type 2 diabetes can cause complications if not managed properly. These include nerve damage, kidney disease, and stroke. You can help prevent these by having regular checkups with your doctor and ...